RLS Global

JANUARY 1st - MARCH 31st (Previous year in brackets)

• Net sales amounted to TSEK 89 (TSEK 305)
• Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3)
• Earnings per share after dilution at SEK -0,09 (SEK 0,07)
• Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730)
• Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7)
• Equity ratio was 82 % (77 %) 

Summary of events during FIRST quarter

• An extra AGM was held 9 February.
• Lars Johansson was elected Board Member and Chairman of the Board at the extra AGM.
• Wounds UK publishes the peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel". The article concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity, in vitro, compared to other debridement products and techniques.

Summary of events after FIRST quarteR

• The UK MHRA (Medicines & Healthcare products Regulatory Agency) has approved RLS' application to extend the current clinical study for pressure ulcers to UK.
• Eva Jagenheim leaves her role as CFO in RLS Global AB. She will remain in service during her notice period, at latest to October, to ensure a smooth transition to her successor.

The Interim Report Q1, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/

Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on May 31st 2023.